Prognostic Factors Associated With Increased Mortality in Pediatric Veno‐Occlusive Disease Following Hematopoietic Cell Transplantation
Clinical Transplantation · 2024
DOI: 10.1111/ctr.70037 ↗At a glance
Journal article in Clinical Transplantation, 2024. Written by Irina Zaidman and 6 co-authors. Institution: Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel. Major MEDLINE topics: Hematopoietic Stem Cell Transplantation, Hepatic Veno-Occlusive Disease. Cited 3 times so far (Crossref); 26 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Background
Hepatic veno‐occlusive disease (VOD) is a life‐threatening complication of hematopoietic cell transplantation (HCT) and is categorized as a transplant‐related, systemic endothelial disease. Severe VOD can lead to multi‐organ dysfunction (MOF) and is associated with a high mortality rate.
Objective
To evaluate the incidence of VOD in children after HCT and analyze the outcomes and risk factors associated with increased mortality. Study Design A retrospective cohort study of 1243 children with malignant and non‐malignant diseases who underwent HCT at two large pediatric centers over 20 years.
Results
One hundred one patients (8%) developed VOD post HCT. Most patients developed VOD post allogeneic HCT (76%) versus autologous (24%). The incidence of VOD was twice as high in children with malignant diseases compared to non‐malignant (68% vs. 32%). A much higher incidence of VOD occurred in patients after a busulfan‐based regimen versus total body irradiation‐based and treosulfan‐based, 73%, 18%, and 1%, respectively. The 100‐day survival rate of HCT patients with VOD was 69%. The overall survival rate of the entire group was 50%, showing improvement over the span of the study years, from 40% between 2000 and 2009 to 63% between 2010 and 2021 ( p = 0.022). Factors associated with increased mortality included infections before transplant ( p = 0.013), conditioning regimen ( p = 0.01), abnormal liver function ( p = 0.019), presence of ascites ( p = 0.008), MOF ( p < 0.001), and the need for admission to a pediatric intensive care unit ( p < 0.001). There was no significant difference in survival rates between children treated with defibrotide alone or with those treated with defibrotide and steroids (61% and 65%, respectively; p = 0.685).
Conclusions
Severe VOD in pediatric patients following HCT remains a life‐threatening complication with a high mortality rate. Early diagnosis and treatment with defibrotide are critical for managing this condition. In our cohort, the addition of steroids to defibrotide was not associated with improved outcomes.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
- Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
- Division of Pediatric Critical Care, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
- Division of Pediatric Hematology Oncology and Bone Marrow Transplantation, Ruth Rappaport Children's Hospital, Rambam Medical Center, Haifa, Israel.
ORCID profiles: Irina Zaidman, Ehud Even-Or
Cite
APA
Zaidman, I., Barsoum, N., Even-Or, E., Daher, M., Aran, A. A., Stepensky, P., & Gefen, A. (2024). Prognostic Factors Associated With Increased Mortality in Pediatric Veno‐Occlusive Disease Following Hematopoietic Cell Transplantation. Clinical Transplantation. https://doi.org/10.1111/ctr.70037
Vancouver
Zaidman I, Barsoum N, Even-Or E, Daher M, Aran AA, Stepensky P, et al. Prognostic Factors Associated With Increased Mortality in Pediatric Veno‐Occlusive Disease Following Hematopoietic Cell Transplantation. Clinical Transplantation. 2024. doi:10.1111/ctr.70037
BibTeX
@article{Zaidman2024,
author = {Zaidman, Irina and Barsoum, Natalie and Even-Or, Ehud and Daher, Miriam and Aran, Adi Avniel and Stepensky, Polina and Gefen, Aharon},
title = {Prognostic Factors Associated With Increased Mortality in Pediatric Veno‐Occlusive Disease Following Hematopoietic Cell Transplantation},
journal = {Clinical Transplantation},
year = {2024},
doi = {10.1111/ctr.70037}
}
EUVIMED